Shenzhen YHLO Biotech Co., Ltd. (YHLO) is an immunoassay solutions company that specializes in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents with own intellectual properties. Based on the technology platforms of chemiluminescence (CLIA), monotest ELISA, line immunoblot, immunofluorescence, YHLO has developed hundreds of test items on autoimmunity, reproductive health, diabetes, infection and routine immunochemistry. YHLO is one of the very few suppliers in China for autoimmune instruments and reagents, and has launched China`s first monotest ELISA analyzer – UNION, China`s first ESR analyzer with direct EDTA tube testing – VISION, China`s first high-speed Chemiluminescence System - iFlash 3000 CLIA System (300 T/H), and China`s first autoimmune assays in CLIA, LIA and ELISA platforms. YHLO has also launched Anti-Müllerian Hormone (AMH) dedicated to ELISA and CLIA systems, as well as the world`s first CLIA assays for Inhibin B, Adiponectin, ZnT8A, RA33, etc. In 2020, YHLO launched CLIA assays of SARS-CoV-2 IgM and IgG to aid the diagnosis of COVID-19.